» Articles » PMID: 24952744

Ordering of Mutations in Preinvasive Disease Stages of Esophageal Carcinogenesis

Abstract

Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) provides an ideal model to study the ordering of somatic mutations. We identified recurrently mutated genes and assessed clonal structure using whole-genome sequencing and amplicon resequencing of 112 EACs. We next screened a cohort of 109 biopsies from 2 key transition points in the development of malignancy: benign metaplastic never-dysplastic Barrett's esophagus (NDBE; n=66) and high-grade dysplasia (HGD; n=43). Unexpectedly, the majority of recurrently mutated genes in EAC were also mutated in NDBE. Only TP53 and SMAD4 mutations occurred in a stage-specific manner, confined to HGD and EAC, respectively. Finally, we applied this knowledge to identify high-risk Barrett's esophagus in a new non-endoscopic test. In conclusion, mutations in EAC driver genes generally occur exceptionally early in disease development with profound implications for diagnostic and therapeutic strategies.

Citing Articles

Unraveling the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma: the "omics" era.

Barchi A, DellAnna G, Massimino L, Mandarino F, Vespa E, Viale E Front Oncol. 2025; 14:1458138.

PMID: 39950103 PMC: 11821489. DOI: 10.3389/fonc.2024.1458138.


Does radiofrequency ablation of the lower oesophagus allow for clonal expansion of highly mutated neosquamous epithelium?.

Akarca F, Shaheen N, Stachler M BMJ Oncol. 2025; 2(1):e000089.

PMID: 39886511 PMC: 11203143. DOI: 10.1136/bmjonc-2023-000089.


Is post-ablation neo-squamous epithelium genomically predisposed to malignant progression?.

Black E, Fitzgerald R BMJ Oncol. 2025; 2(1):e000183.

PMID: 39886506 PMC: 11234994. DOI: 10.1136/bmjonc-2023-000183.


Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.

Ganguli P, Basanta C, Acha-Sagredo A, Misetic H, Armero M, Mendez A Nat Cancer. 2025; 6(1):158-174.

PMID: 39753721 PMC: 11779637. DOI: 10.1038/s43018-024-00876-0.


Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

Scanlon E, Lavery A, Albraikat M, Stevenson L, Kennedy C, Byrne R ESMO Open. 2024; 9(11):103930.

PMID: 39395265 PMC: 11693431. DOI: 10.1016/j.esmoop.2024.103930.


References
1.
Larson D, Harris C, Chen K, Koboldt D, Abbott T, Dooling D . SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2011; 28(3):311-7. PMC: 3268238. DOI: 10.1093/bioinformatics/btr665. View

2.
Goh X, Rees J, Paterson A, Chin S, Marioni J, Save V . Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut. 2011; 60(10):1317-26. DOI: 10.1136/gut.2010.234179. View

3.
Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

4.
Lao-Sirieix P, Boussioutas A, Kadri S, ODonovan M, Debiram I, Das M . Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut. 2009; 58(11):1451-9. DOI: 10.1136/gut.2009.180281. View

5.
Bass A, Lawrence M, Brace L, Ramos A, Drier Y, Cibulskis K . Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011; 43(10):964-968. PMC: 3802528. DOI: 10.1038/ng.936. View